Antares Pharma appoints Peter Greenleaf to its Board of Directors

– USA, NJ – Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.

Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, “We are pleased to announce the addition of a seasoned pharmaceutical executive to the Antares Board of Directors. Peter Greenleaf joins Antares at an important time in our Company’s history. We believe his experience in commercial operations and strategy functions will serve to compliment the Antares team as we prepare to launch XYOSTED and any potential future products. We look forward to Peter’s contributions.”

About Peter Greenleaf

Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on neurological and pediatric disorders. He is also Chairman of the Board at BioDelivery Sciences (NASDAQ:BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.

Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Prior to joining Sucampo Pharmaceuticals, Mr. Greenleaf held senior positions spanning commercial, corporate development and strategy functions at several pharmaceutical companies. Notably, he served as President of Medimmune LLC, the biologics arm of AstraZeneca, and President of Medimmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Mr. Greenleaf is currently a member of the Board of Directors of Eyetech Pharmaceuticals and was previously a member of the Board of Directors of the Biotechnology Industry Organization (BIO) serving on the Governing Boards of the Emerging Companies and Health Sectors. He earned his M.B.A. from St. Joseph’s University and a B.S. from Western Connecticut University.

“I am pleased to be joining Antares Pharma during this exciting period of time for the Company,” said Peter S. Greenleaf. “Three new drug device combination product approvals in 2018 could significantly impact revenue growth in 2019 and beyond, resulting in a positive effect on value creation for our shareholders. I look forward to sharing my expertise and industry experience as we work to expand our existing business.”

About Antares Pharma

Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

For more information : https://www.antarespharma.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>